A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
- Conditions
- Kidney Disease, Chronic
- Interventions
- Registration Number
- NCT05182840
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study.
The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin.
In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine.
In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine.
Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call.
Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 714
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517 BI 690517 - Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517 BI 690517 - Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517 BI 690517 - Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517 Placebo to BI 690517 - Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517 Placebo to empagliflozin - Run-in period: 10 mg empagliflozin Empagliflozin - Run-in period: Placebo to empagliflozin 10 mg Placebo to empagliflozin - Treatment period: 10 mg empagliflozin + 3 mg BI 690517 BI 690517 - Treatment period: 10 mg empagliflozin + 3 mg BI 690517 Empagliflozin - Treatment period: 10 mg empagliflozin + 10 mg BI 690517 BI 690517 - Treatment period: 10 mg empagliflozin + 10 mg BI 690517 Empagliflozin - Treatment period: 10 mg empagliflozin + 20 mg BI 690517 BI 690517 - Treatment period: 10 mg empagliflozin + 20 mg BI 690517 Empagliflozin - Treatment period: 10 mg empagliflozin + Placebo to BI 690517 Placebo to BI 690517 - Treatment period: 10 mg empagliflozin + Placebo to BI 690517 Empagliflozin - Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517 Placebo to empagliflozin - Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517 Placebo to empagliflozin - Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517 Placebo to empagliflozin -
- Primary Outcome Measures
Name Time Method Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. The adjusted mean change (95% confidence interval) in log transformed FMV UACR from baseline at 14 weeks is presented.
The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for all patients is presented.
Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline).
MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented.
The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented.
Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline).
MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of empagliflozin in the Run-in period is presented.
The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period. Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of empagliflozin in the Run-in period is presented.
Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline).
MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.
- Secondary Outcome Measures
Name Time Method UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF) UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
LOCF uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF) UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks.
LOCF uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 week. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF) UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
LOCF uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF) UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks.
LOCF uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach. Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
The missing as non-responder imputes patients with missing Week 14 data as non-responders.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach. Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period. Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks.
Complete case analysis used patients with both baseline and Week 14 data available.
Trial Locations
- Locations (202)
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
PrimeCare Medical Group
🇺🇸Houston, Texas, United States
Suwa Red Cross Hospital
🇯🇵Nagano, Suwa, Japan
Miho Clinic
🇯🇵Tokyo, Shinagawa-ku, Japan
Robert Koch Clinic Sofia
🇧🇬Sofia, Bulgaria
Recherche GCP Research
🇨🇦Montreal, Quebec, Canada
Centro de Pesquisa Clinica - CPCLIN
🇧🇷Sao Paulo, Brazil
The Bailey Clinic
🇨🇦Red Deer, Alberta, Canada
Shivinder Jolly, Nephrologist
🇨🇦Waterloo, Ontario, Canada
BR Trials
🇧🇷Sao Paulo, Brazil
Sameh Fikry Medicine Professional Corporation
🇨🇦Waterloo, Ontario, Canada
Citydiabetes, Stockholm
🇸🇪Stockholm, Sweden
Istanbul University
🇹🇷Istanbul, Turkey
Hospital do RIM - UNIFESP
🇧🇷São Paulo, Brazil
Meitetsu Hospital
🇯🇵Aichi, Nagoya, Japan
Clearview Medical Research, LLC
🇺🇸Canyon Country, California, United States
A.O. Policlinico Giovanni XXIII di Bari
🇮🇹Bari, Italy
ASST Papa Giovanni XXIII - A.O. Papa Giovanni XXIII
🇮🇹Bergamo, Italy
TOSAKI Clinic for Diabetes and Endocrinology
🇯🇵Aichi, Nagoya, Japan
MILAN KVAPIL s.r.o.
🇨🇿Pribram, Czechia
Omihachiman Community Medical Center
🇯🇵Shiga, Omihachiman, Japan
Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
🇩🇪Bad Oeynhausen, Germany
Nagoya Kyoritsu Hospital
🇯🇵Aichi, Nagoya, Japan
Cardiologicum Dresden und Pirna
🇩🇪Dresden, Germany
Universitätsklinikum Carl Gustav Carus Dresden
🇩🇪Dresden, Germany
DRC Drug Research Ltd
🇭🇺Balatonfured, Hungary
National Hospital Organization Takasaki General Medical Center
🇯🇵Gumma, Takasaki, Japan
Kyoto Okamoto Memorial Hospital
🇯🇵Kyoto, Kuse-gun, Japan
Inje University Ilsan Paik Hospital
🇰🇷Goyang, Korea, Republic of
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Iatros International
🇿🇦Bloemfontein, South Africa
General Hospital of Athens "Laiko"
🇬🇷Athens, Greece
Yamaura Medical Clinic
🇯🇵Ueda, Nagano, Japan
Daiyukai Clinic
🇯🇵Aichi, Ichinomiya, Japan
Asano Clinic
🇯🇵Saitama, Kawagoe, Japan
Universitätsklinikum Würzburg AÖR
🇩🇪Würzburg, Germany
Synexus Clinical Research GmbH
🇩🇪Leipzig, Germany
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Tokyo Medical University Hachioji Medical Center
🇯🇵Tokyo, Hachioji, Japan
SMG-SNU Boramae Medical Center
🇰🇷Seoul, Korea, Republic of
Synexus Helderberg Clinical Research Centre
🇿🇦Cape Town, South Africa
Latiff, GHVM
🇿🇦Durban, South Africa
DJW Navorsing
🇿🇦Krugersdorp, South Africa
Centralsjukhuset, Kristianstad
🇸🇪Kristianstad, Sweden
Elixia Upland, LLC
🇺🇸Upland, Pennsylvania, United States
CEDIC - Centro de Investigacion Clinica
🇦🇷Caba, Argentina
Fundación Jiménez Díaz
🇪🇸Madrid, Spain
Paarl Research Centre
🇿🇦Cape Town, South Africa
Synexus Watermeyer Clinical Research Centre
🇿🇦Pretoria, South Africa
Diabetes & Endocrinology Associates of Stark County
🇺🇸Canton, Ohio, United States
Universal Research Group, LLC
🇺🇸Tacoma, Washington, United States
West Orange Endocrinology
🇺🇸Ocoee, Florida, United States
Universitetssjukhuset, Linköping
🇸🇪Linköping, Sweden
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Knoxville Kidney Center PLLC
🇺🇸Knoxville, Tennessee, United States
Hospital Puerta de Hierro
🇪🇸Majadahonda, Spain
TREAD Research
🇿🇦Cape Town, South Africa
Langeberg Clinical Trials
🇿🇦Cape Town, South Africa
University Hospital of Lausanne
🇨🇭Lausanne, Switzerland
Monument Health
🇺🇸Rapid City, South Dakota, United States
Pacific Renal Associates
🇺🇸Long Beach, California, United States
Horizon Research Group
🇺🇸Coral Gables, Florida, United States
Academy Of Diabetes, Thyroid And Endocrine, PA
🇺🇸El Paso, Texas, United States
Valley Clinical Trials, Inc.
🇺🇸Northridge, California, United States
Hospital Público Da Mariña
🇪🇸Burela, Spain
Triad Internal Medicine
🇺🇸Asheboro, North Carolina, United States
Aa Mrc Llc
🇺🇸Flint, Michigan, United States
Lucas Research, Inc.
🇺🇸Morehead City, North Carolina, United States
CIMEL centro de Investigaciones Médicas Lanús
🇦🇷Buenos Aires, Argentina
Amicis Research Center
🇺🇸Northridge, California, United States
Providence Medical Research Center
🇺🇸Spokane, Washington, United States
Aventiv Research Inc.
🇺🇸Mesa, Arizona, United States
Simcare Medical Research, LLC
🇺🇸Sugar Land, Texas, United States
Elixia Fort Lauderdale, LLC
🇺🇸Fort Lauderdale, Florida, United States
South Florida Research Institute
🇺🇸Lauderdale Lakes, Florida, United States
Glenny Corp. S.A. Bioclinica Argentina
🇦🇷Ciudad Autonoma Buenos Aires, Argentina
Elixia Tampa, LLC
🇺🇸Temple Terrace, Florida, United States
Hospital Universitario Reina Sofía
🇪🇸Córdoba, Spain
Pines Care Research Center
🇺🇸Pembroke Pines, Florida, United States
Kansas Nephrology Research Institute, LLC
🇺🇸Wichita, Kansas, United States
Research Institute of Dallas
🇺🇸Dallas, Texas, United States
Monash University
🇦🇺Box Hill, Victoria, Australia
Cedar Crosse Research Center
🇺🇸Chicago, Illinois, United States
Instituto Privado de Investigaciones Clínica Córdoba S.A.
🇦🇷Cordoba, Argentina
John Hunter Hospital
🇦🇺New Lambton Heights, New South Wales, Australia
Centro de Salud Renal Junín
🇦🇷Junín, Argentina
San Marcus Research Clinic, Inc.
🇺🇸Miami, Florida, United States
Total Research Group, LLC
🇺🇸Miami, Florida, United States
Horizon Research Group, LLC
🇺🇸Miami, Florida, United States
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
The First Afiliated Hospital, Sun Yet-sen University
🇨🇳Guangzhou, China
Zhejiang Province People's Hospital
🇨🇳Hangzhou, China
Huashan Hospital, Fudan University
🇨🇳Shanghai, China
Shanghai Fifth People's Hospital affiliated to Fudan University
🇨🇳Shanghai, China
Medical Center Rusemed
🇧🇬Ruse, Bulgaria
Tampere University Hospital
🇫🇮Tampere, Finland
MHAT Prof Stoyan Kirkovich AD
🇧🇬Stara Zagora, Bulgaria
Markhot Ferenc Hospital, Eger
🇭🇺Eger, Hungary
SMS Medical College and HospitaL
🇮🇳Jaipur, India
All India Institute of Medical Sciences
🇮🇳New Delhi, India
Shree Giriraj Multispeciality Hospital
🇮🇳Rajkot, India
Government Medical College & Hospital
🇮🇳Aurangabad, India
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
🇲🇽Mexico, Mexico
Clinstile S.A. de C.V.
🇲🇽México, Mexico
CEDOPEC-Ctro Esp en Diab, Obesidad y Prev de Enf Cardiovasc
🇲🇽México, Mexico
Davao Doctors Hospital
🇵🇭Davao City, Philippines
Philippine Heart Center
🇵🇭Quezon City, Philippines
NZOZ Specialized Ambulance "MEDICA"
🇵🇱Lublin, Poland
Charleroi - UNIV CHU de Charleroi
🇧🇪Lodelinsart, Belgium
Medical Center Synexus Sofia EOOD
🇧🇬Sofia, Bulgaria
"Attiko" Hospital of Athens
🇬🇷Athens, Greece
Univ. Gen. Hosp. of Ioannina
🇬🇷Ioannina, Greece
Semmelweis University
🇭🇺Budapest, Hungary
Synexus Hungary Healthcare Service Ltd.
🇭🇺Budapest, Hungary
Satucon Oy
🇫🇮Kuopio, Finland
Lausmed Kft. Outpatient Unit of Internal Medicine
🇭🇺Baja, Hungary
BKS Research Ltd
🇭🇺Hatvan, Hungary
Ganesh Shankar Vidyarthi Memorial Medical College
🇮🇳Kanpur, India
Tuanku Fauziah Hospital
🇲🇾Kangar, Malaysia
Unidad de Investigación Clinica y Atencion Medica HEPA SC
🇲🇽Guadalajara, Mexico
Akershus Universitetssykehus HF
🇳🇴Nordbyhagen, Norway
Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice
🇵🇱Katowice, Poland
Omedica Medical Centre, Poznan
🇵🇱Poznan, Poland
Synexus Poland, Branch in Poznan
🇵🇱Poznan, Poland
Barwijuk Clinics
🇵🇱Warszawa, Poland
Jaipur National University Institute for Medical Science & Research Centre
🇮🇳Jaipur, India
K R Hospital Mysore Medical College and Research Centre
🇮🇳Mysore, India
Galaxy Lifecare Services Pvt. Ltd.
🇮🇳Varanasi, India
Christian Medical College
🇮🇳Vellore, India
Hospital Raja Perempuan Zainab II, Kota Bharu
🇲🇾Kota Bharu, Malaysia
Hospital Seri Manjung
🇲🇾Seri Manjung, Malaysia
Centro Mexicano de Desarrollo de Estudios Clínicos SA -CEMDEC
🇲🇽Mexico, Mexico
INTERCORE Medical Center
🇵🇱Bydgoszcz, Poland
Pro Familia Altera
🇵🇱Katowice, Poland
Hospitals of Tczew S.A.
🇵🇱Pomorskie, Poland
Medical Center HCP Sp. z o.o
🇵🇱Poznan, Poland
Kingsway Hospitals
🇮🇳Nagpur, India
West Visayas State University Medical Center
🇵🇭Iloilo City, Philippines
Synexus Polska SCM Sp. z o.o. Gdansku, Gdansk
🇵🇱Gdansk, Poland
Synexus Lodz Medical Center
🇵🇱Lodz, Poland
Synexus Poland, Branch in Wroclaw
🇵🇱Wroclaw, Poland
ULS de Almada -Seixal, E. P. E. - Hospital Garcia de Orta
🇵🇹Almada, Portugal
ULS da Região de Aveiro
🇵🇹Aveiro, Portugal
Brussels - UNIV UZ Brussel
🇧🇪Brussel, Belgium
Brussels - UNIV Saint-Luc
🇧🇪Bruxelles, Belgium
St Vincent's Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Hospital Selayang
🇲🇾Batu Caves, Malaysia
University Kebangsaan Malaysia
🇲🇾Cheras, Kuala Lumpur, Malaysia
Hospital Universitario Dr Jose Eleuterio Gonzalez
🇲🇽Nuevo León, Mexico
Helse Stavanger, Stavanger Universitetssykehus
🇳🇴Stavanger, Norway
Norzel Medical and Diagnostic Clinic
🇵🇭Cebu City, Philippines
The Medical City
🇵🇭Pasig City, Philippines
Senor Santo Nino Hospital
🇵🇭Tarlac, Philippines
ULS da Região de Leiria, E.P.E.
🇵🇹Leiria, Portugal
ULS de Gaia/Espinho, EPE
🇵🇹Vila Nova de Gaia, Portugal
Centrum Medyczne Synexus
🇵🇱Warszawa, Poland
CHLO, EPE - Hospital de Santa Cruz
🇵🇹Carnaxide, Portugal
La Louvière - UNIV CHU Tivoli
🇧🇪La Louvière, Belgium
Forte Family Practice
🇺🇸Las Vegas, Nevada, United States
AKDHC Medical Research Services, LLC
🇺🇸Phoenix, Arizona, United States
Colorado Kidney Care
🇺🇸Denver, Colorado, United States
Ina Central Hospital
🇯🇵Nagano, Ina, Japan
The University of Tokyo Hospital
🇯🇵Tokyo, Bunkyo-ku, Japan
DaVita Clinical Research Germany GmbH
🇩🇪Düsseldorf, Germany
California Kidney Specialists
🇺🇸San Dimas, California, United States
Hospital Universitário João de Barros Barreto
🇧🇷Belém, Brazil
UZ Leuven
🇧🇪Leuven/Vlaams-Brabant, Belgium
Ruschel Medicina e Pesquisa Clínica
🇧🇷Rio de Janeiro, Brazil
Fundação Pró Renal Brasil
🇧🇷Curitiba, Brazil
Faculdade de Medicina de Botucatu - UNESP
🇧🇷Botucatu, Brazil
CEMEC - Centro Multidisciplinar de Estudos Clínicos
🇧🇷São Bernardo do Campo, Brazil
Universidade Federal do Rio Grande do Sul
🇧🇷Porto Alegre, Brazil
LMC Clinical Research Inc. (Brampton)
🇨🇦Brampton, Ontario, Canada
The First People's Hospital of Nanning
🇨🇳Nanning, China
DIKa centrum s.r.o.
🇨🇿Havirov, Czechia
Synexus Czech s.r.o.
🇨🇿Prague, Czechia
Hospital Slany, Internal Department
🇨🇿Slany, Czechia
Turku University Hospital / TYKS
🇫🇮Turku, Finland
Institut für klinische Forschung und Entwicklung (IKFE) Berlin GmbH
🇩🇪Berlin, Germany
Iatriko of Athens Group/ Iatriko of P. Faliro
🇬🇷P. Faliro, Greece
University Debrecen Hospital
🇭🇺Debrecen, Hungary
Korea University Ansan Hospital
🇰🇷Ansan, Korea, Republic of
Klinik Kesihatan Mahmoodiah
🇲🇾Johor Bahru, Malaysia
Chungbuk National University Hospital
🇰🇷Cheongiu, Korea, Republic of
Centro de Investigacion Cardiometabolica de Aguascalientes
🇲🇽Aguascalientes, Mexico
Institute for Studies on Diabetes Foundation Inc.
🇵🇭Marikina city, Philippines
Clinical Best Solutions
🇵🇱Lublin, Poland
APDP - Associação Protectora dos Diabéticos de Portugal
🇵🇹Lisboa, Portugal
Elite Research Center, LLC
🇺🇸Flint, Michigan, United States
New Mexico Clinical Research and Osteoporosis Center, Inc.
🇺🇸Albuquerque, New Mexico, United States
Heritage Valley Medical Group
🇺🇸Beaver, Pennsylvania, United States
P&I Clinical Research, LLC
🇺🇸Lufkin, Texas, United States
Centro de Investigaciones Médicas Mar del Plata
🇦🇷Mar del Plata, Argentina
CEMEDIC - Centro de Especialidades Medicas
🇦🇷Villa Luro, Argentina
Instituto Médico Catamarca - IMEC
🇦🇷Rosario, Argentina
Boise Kidney and Hypertension PLLC
🇺🇸Nampa, Idaho, United States
Clinical Research Consultants, LLC
🇺🇸Kansas City, Missouri, United States
Clinical Research of Brandon LLC
🇺🇸Brandon, Florida, United States
Prince of Wales Hospital
🇭🇰Hong Kong, Hong Kong
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong